KEYTRUDA® (pembrolizumab)

Pembrolizumab (Keytruda®) is a programmed death receptor-1 (PD-1) blocking antibody that enhances T-cell immune responses against tumor cells. It is FDA-approved for multiple malignancies including melanoma, NSCLC, mesothelioma, HNSCC, Hodgkin lymphoma, PMBCL, urothelial carcinoma, MSI-H/dMMR solid tumors, gastric/GEJ adenocarcinoma, esophageal carcinoma, cervical cancer, hepatocellular carcinoma, biliary tract cancer, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, TMB-H tumors, cutaneous squamous cell carcinoma, triple-negative breast cancer, and others. >